In Vitro Fertilization Market Set for Robust Growth, Expected to Register a 7.8% CAGR Through 2032

The global in vitro fertilization (IVF) market was valued at US$ 19.5 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 7.8% from 2023 to 2032. This market is driven by several factors including the rising incidence of infertility among men and women, advancements in IVF technology, and the increasing age of first-time mothers which contributes to fertility issues.

However, the market faces challenges such as high treatment costs, which can be prohibitive for many couples, and complex ethical, legal, and emotional issues associated with IVF. The success rates of IVF treatments can vary significantly based on age and underlying fertility issues, which can also add to the emotional and financial stress experienced by patients.

Recent developments in the market have focused on enhancing the effectiveness and accessibility of treatments. For instance, Europe has seen growth driven by medical tourism, with more affordable treatment options available in countries like the Czech Republic. There have also been regulatory improvements and the introduction of innovative products that enhance the success rates of IVF procedures. Additionally, companies are increasingly focusing on expanding their geographic presence and improving their service offerings in developing markets, which are becoming more significant due to rising infertility rates and increased healthcare expenditure.

Key Takeaways

• In 2022, the global in vitro fertilization (IVF) market was valued at $19.5 billion, with an anticipated compound annual growth rate (CAGR) of 7.8% through 2032.
• IVF treatments incorporating intracytoplasmic sperm injection (ICSI) constituted 43% of the market share, preferred for its efficacy in treating male infertility.
• The equipment sector is projected to claim 59% of the market, spurred by the proliferation of IVF procedures and advancements in technology.
• Fresh non-donor IVF cycles are predicted to see substantial growth in demand due to their higher success rates with fresh eggs.
• Fertility clinics are leading the market, capturing over 79% of revenue, propelled by growing demand and enhanced accessibility.
• An increase in delayed pregnancies has escalated IVF adoption worldwide, linking rising infertility rates to postponed childbearing.
• The practice of transferring multiple embryos during IVF is linked to heightened risks of premature birth and low birth weight, influencing market dynamics.
• Affordable IVF treatments in countries like India and Brazil are enhancing their appeal as destinations for medical tourism in the fertility sector.

Get Sample PDF Report: https://market.us/report/in-vitro-fertilization-market/request-sample/

In Vitro Fertilization Market Key Segments

Based on Type

• Conventional IVF
• IVF with ICSI
• IVF with Donar Eggs
• Other Types

Based on Product

• Equipment
• Sperm Analyzer Systems
• Imaging Systems
• Ovum Aspiration Pumps
• Micromanipulator Systems
• Other Equipment
• Reagents & Media
• Cryopreservation Media
• Embryo Culture Media
• Ovum Processing Media
• Sperm Processing Media
• Other Reagents & Media

Based on Cycle Type

• Fresh IVF Cycles (Non-Donor)
• Thawed IVF Cycles (Non-Donor)
• Donor Egg IVF Cycles

Based on End-User

• Fertility Clinics
• Surgical Centers
• Hospitals
• Research Institutes
• Other End-Users

Key Regions

• North America (The US, Canada, Mexico)
• Western Europe (Germany, France, The UK, Spain, Italy, Portugal, Ireland, Austria, Switzerland, Benelux, Nordic, Rest of Western Europe)
• Eastern Europe (Russia, Poland, The Czech Republic, Greece, Rest of Eastern Europe)
• APAC (China, Japan, South Korea, India, Australia & New Zealand, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam, Rest of APAC)
• Latin America (Brazil, Colombia, Chile, Argentina, Costa Rica, Rest of Latin America)
• Middle East & Africa (Algeria, Egypt, Israel, Kuwait, Nigeria, Saudi Arabia, South Africa, Turkey, United Arab Emirates, Rest of MEA)

Buy Directly: https://market.us/purchase-report/?report_id=67275

Key Players Analysis

OvaScience, a biotechnology company, is actively advancing the field of reproductive medicine with innovative approaches to in vitro fertilization (IVF). The company focuses on developing treatments that increase a woman’s egg reserve and improve fertility without the need for hormone injections. Notably, OvaScience has introduced OvaPrime, a treatment aimed to enhance egg reserves, and OvaTure, a potential new IVF treatment designed to generate fertilizable eggs directly from ovarian stem cells. Their AUGMENT treatment, available in select markets outside the U.S., is designed to improve IVF success rates by enhancing egg health using mitochondria from precursor cells. With a strategic focus on research and development, OvaScience recently streamlined operations to prioritize these innovative treatments, expecting to drive forward clinical trials and treatment availability.

FUJIFILM Irvine Scientific, a leader in cell culture media and assisted reproductive technologies, actively enhances in vitro fertilization (IVF) outcomes through innovative solutions. The company offers advanced AI and medical imaging tools aimed at improving IVF success rates by facilitating non-invasive, reliable assessments of embryo viability and genetic integrity. Notably, its Life Whisperer platform incorporates AI to objectively score embryo quality, potentially boosting clinical pregnancy chances by analyzing morphological features. Additionally, FUJIFILM Irvine Scientific’s Vit Kit-NX, part of their vitrification solutions, aids in the high-yield survival of oocytes and embryos, reflecting their commitment to advancing reproductive technologies globally.

EMD Serono Inc., a prominent player in the global In-Vitro Fertilization (IVF) market, has been instrumental in advancing IVF technologies. A key innovation from EMD Serono is the Eeva Test, a non-invasive assessment tool that enhances traditional embryo viability evaluations. Launched in Canada, this technology utilizes time-lapse imaging and software analysis to predict the development potential of embryos, thus aiding IVF clinicians in decision-making and potentially improving patient outcomes​. This aligns with the growing demand in the IVF sector, driven by increasing infertility rates and technological advancements​. EMD Serono’s contributions reflect significant strides in addressing the challenges within the reproductive health sector.

CooperSurgical Inc. has established a robust presence in the In Vitro Fertilization (IVF) market through its comprehensive range of solutions and technologies aimed at enhancing reproductive health. The company’s portfolio includes innovative products such as the SAGE In-Vitro Maturation Media, designed for the maturation of immature oocytes, fertilization, and embryo development, addressing the needs of patients with specific medical conditions like polycystic ovarian syndrome. Additionally, CooperSurgical has expanded its offerings through acquisitions and the development of advanced equipment under the ORIGIO brand, which includes media and devices essential for IVF procedures. The company’s focus on both product innovation and educational support for medical professionals underscores its commitment to improving clinical outcomes in reproductive care.

Genea Biomedx, a leader in the in vitro fertilization (IVF) sector, is enhancing the IVF process through innovative technologies and strategic partnerships. The company provides advanced medical devices for IVF laboratories, including the Geri time-lapse incubator, which allows for continuous monitoring and assessment of embryo development, aiming to improve clinical outcomes significantly. Additionally, Genea Biomedx has collaborated with AIIVF to integrate AI-driven analytics into their systems, further optimizing IVF care by enabling real-time embryo data analysis. These efforts are bolstered by their CE-marked technologies like the Gavi automated vitrification instrument, which standardizes critical equilibration steps in the vitrification process, and their partnership with Merck KGaA, which aids in global commercialization and adoption of their products.

In Vitro Fertilization Market Key Players:

• OvaScience
• FUJIFILM Irvine Scientific
• EMD Serono Inc.
• CooperSurgical Inc.
• Genea Biomedx
• Thermo Fisher Scientific Inc.
• Progyny Inc.
• Boston IVF
• Other Key Players

In Vitro Fertilization Market Report Scope >> Market Value (2023): USD 19.5 Billion || Forecast Revenue (2033): USD 40.6 Billion || CAGR (2024-2033): 7.8% || Base Year Estimation: 2023 || Historic Period: 2019-2022 || Forecast Period: 2024-2033.

Inquire More about report: https://market.us/report/in-vitro-fertilization-market/#inquiry

About Market.US

Market.US is renowned for its comprehensive market research and analysis, providing customized and syndicated reports to a global clientele. Specializing in a variety of sectors, they offer strategic insights and detailed market forecasts, assisting businesses in making informed decisions. With a focus on innovation and accuracy, Market.US supports clients in over 126 countries, and maintains a strong repeat customer rate, underscoring their commitment to quality and client satisfaction. Their team excels in delivering exceptional research services, ensuring that no detail is overlooked in any target market.

Contact Details
Market.us (Powered By Prudour Pvt. Ltd.)
Contact No: +1 718 618 4351.
Email: inquiry@market.us
Blog: https://medicalmarketreport.com/

View More Trending Reports

Robotic Prosthetics Market Projected to Hit USD 3,212 Million By 2032

Generative AI in Healthcare Market Hit USD 17.2 Billion By 2032

Telecare Market Anticipated To Reach USD 6.8 Billion By 2032

Face Mask Machine Market Predicted USD 27.4 Billion By 2032

Intravascular Ultrasound [IVUS] Devices Market Achieve USD 1296 Million By 2032